IN THE CLAIMS

Please cancel claims 1-9 before calculating the filing fee.

Please amend claims 10-16 as follows:

10. (Amended) A mutant of a naturally occurring second serine/threonine protein kinase or tyrosine protein kinase, said mutant characterized by:

A2

a. having an ATP binding site comprising at least one amino acid substitution [in an ATP binding site as] compared to an ATP binding site of the [a corresponding] naturally occurring second serine/threonine protein kinase or tyrosine protein kinase; and

b. having the ability to bind to a compound that binds to an ATP binding site of a first serine/threonine protein kinase or first tyrosine protein kinase, said binding of the compound with the mutant having [with] a K_i or a K_d that is

(i) [of] less than 10 μM [a compound that binds to an ATP binding site of a first serine/threonine kinase or tyrosine kinase;] and

c. (ii) [the ability to bind said compound with] at least [a] 10-fold lower [K_i or K_d] than the K_i or K_d [for] of the binding of said compound with said naturally-occurring second serine/threonine protein kinase or second tyrosine protein kinase.

11. (Amended) The mutant second protein kinase according to claim 10, wherein said first and said second protein kinases are mitogen activating protein (MAP) kinases.

12. (Amended) The mutant second protein kinase according to claim 11, wherein said mutant second protein kinase is selected from:

a. a mutant extracellular-signal regulated kinase 2 (ERK2) [consisting of] comprising the amino acid sequence [as set forth in] of SEQ ID NO:2, wherein amino acid 105 is threonine or alanine; or

A2 CONT.

b. a mutant Jun-N-terminal kinase 3 (JNK3) comprising amino acids 40-402 of SEQ ID NO:3, wherein amino acid 146 is threonine or alanine.

13. (Amended) The mutant ERK2 [second kinase] according to claim 12, wherein [in SEQ ID NO:2] amino acid 103 is leucine, amino acid 106 is histidine, amino acid 109 is glycine and amino acid 110 is alanine.

14. (Amended) The mutant JNK3 [second kinase] according to claim 12, wherein [in SEQ ID NO:3] amino acid 150 is glycine.

15. (Amended) A crystallizable co-complex of a mutant protein second kinase according to any one of claims 10 to 14 and an inhibitor of said first kinase bound to the ATP binding site of said mutant second protein kinase.

B1

16. (Amended) The crystallizable co-complex according to claim 13, wherein said first protein kinase is p38, said second protein kinase is a MAP kinase and said inhibitor is a pyridinyl-imidazole inhibitor of p38.